###begin article-title 0
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 275 281 275 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 219 224 <span type="species:ncbi:9606">human</span>
Recently, periostin (POSTN), a gene encoding a protein with similarity to the fasciclin family and involved in cell survival and angiogenesis, has emerged as a promising marker for tumor progression in various types of human cancers. There is some controversy regarding both POSTN expression levels and the nature of periostin-producing cells within tumors. In this study, we used quantitative RT-PCR to assess periostin gene expression in normal tissues, primary cell cultures, tumor tissues and tumor cell lines.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 168 174 168 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 302 308 302 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 678 685 678 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 736 742 736 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1215 1221 1215 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1280 1287 <span type="species:ncbi:9606">patient</span>
Periostin expression levels are highly variable in both normal tissues and tumors and strong POSTN overexpression is mostly detected in tumors from pancreas and liver. POSTN is not expressed in blood cancers. In melanoma samples, average periostin expression is not increased in primary tumors whereas POSTN overexpression was detected in about 60% of melanoma metastatic tumors in the liver or lymph nodes. Identification of the cellular source of periostin production in melanoma metastases -cancer cells or stroma- was assessed by comparing periostin expression in 23 newly-established melanoma cell lines and matched tumors. In contrast to the reduction by more than 99% of COL6A3 stromal marker mRNA in all cell lines, significant POSTN transcription was maintained in some melanoma cell lines, suggesting that both stromal cells and melanoma cells express periostin. The high level of periostin expression in primary cultures of skin fibroblasts suggests that fibroblasts may contribute for a large part to periostin production in melanoma-associated stroma. On the other hand, periostin expression in melanoma cells is probably acquired during the tumorigenic process as 1) normal melanocytes do not express POSTN and 2) melanoma cells from distinct metastases of the same patient were associated with very different levels of periostin expression.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
Our comparative analysis suggests that, although periostin overexpression is clearly detected in some cancers, it is not a general feature of tumors. In melanoma, our study identifies both stromal and melanoma cells as sources of periostin production and correlates POSTN expression levels with increased primary tumor thickness and metastatic process development.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 653 654 653 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 902 903 896 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 935 936 925 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">V</sub>
###xml 940 942 927 929 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 951 952 934 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink">V</sub>
###xml 956 958 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5 </sub>
###xml 1128 1129 1108 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1130 1131 1110 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1198 1199 1174 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 1203 1205 1176 1178 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 1328 1329 1301 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 589 594 <span type="species:ncbi:10090">mouse</span>
###xml 800 805 <span type="species:ncbi:9606">human</span>
A better understanding of the molecular mechanisms involved in melanoma and cancer progression in general is undoubtedly a major challenge in the development of new diagnostic and therapeutic approaches, underlying the necessity to identify new molecular targets. During the past decade, global gene expression profiling studies on various human cancer types, mainly relying on cDNA microarray technology, led to the identification of new candidate genes involved in cancer progression. These included periostin (POSTN), a gene encoding a secreted 90 kDa protein initially identified in a mouse osteoblastic library as a putative bone adhesion protein [1]. This protein shows sequence similarity to fasciclin I, an insect cell adhesion protein involved in central nervous system development [2], and human beta IgH3, a TGF-beta 1-induced protein promoting adhesion and spreading of dermal fibroblasts [3]. Binding of periostin to alphaVbeta3 and alphaVbeta5 integrins has been reported to promote cell adhesion and spreading and to activate the Akt/PKB signaling pathway leading to increased cellular survival and angiogenesis [4-6]. In pancreatic cancer cells, periostin was shown to bind to alpha6beta4 integrin, thereby promoting phosphorylation of focal adhesion kinase and PKB through activation of the PI3 kinase pathway [7].
###end p 9
###begin p 10
###xml 95 96 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 651 657 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 846 848 846 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 954 963 954 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 964 965 964 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 969 971 969 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1064 1066 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1174 1176 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1179 1186 1179 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 1218 1224 1218 1224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1348 1349 1348 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1350 1351 1350 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 1300 1309 <span type="species:ncbi:10090">nude mice</span>
###xml 1437 1442 <span type="species:ncbi:10090">mouse</span>
Over the past seven years, periostin was proposed to be a novel therapeutic target for cancer [8]. Indeed, POSTN gene was found to be overexpressed in various human cancers such as ovary [4,9], colon [6], pancreas [7,10], thyroid [11], oral squamous cell carcinoma [12,13], breast [5], lung [14] and neuroblastoma [15] and higher POSTN expression levels were correlated with increased tumor aggressiveness and/or poorer survival in NSLC [14,16], SCLC [17], neuroblastoma [15], colon cancers [6], thyroid carcinomas [11], oral squamous cell carcinoma [12] and pancreatic ductal adenocarcinoma [10]. However, other studies reported a down-regulation of POSTN transcription in bladder [18] and lung [19] cancer. The functional role of periostin in cancer is also under debate as both tumor-promoting [5-7,10,20,21] and tumor-suppressing activities [18,19] have been reported: on one hand, periostin was reported to increase invasiveness of tumor cell lines in vitro [7,12,20] but, on the other hand, periostin expression reduced invasiveness of bladder cancer cells [18] and decreased anchorage-independent growth of T24 bladder cancer cells and SaOS-2 osteosarcoma cell line [19]. In vivo, two reports demonstrated that POSTN overexpression in tumor cell lines increases metastasis and angiogenesis in nude mice and reduces stress-induced apoptosis [5,6] while another report provided evidence that periostin suppresses lung metastasis of mouse melanoma cell line B16-F10 [18].
###end p 10
###begin p 11
###xml 9 15 9 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 195 201 195 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 491 499 491 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 540 546 540 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Although POSTN overexpression does not seem to be systematic in human tumors, studies agree on the low level of periostin expression in most tumor cell lines [4,7,9,13,18,19,21]. Lower levels of POSTN expression in tumor cell lines compared to tumor tissues are in agreement with studies showing a production of periostin by stromal cells -and not cancer cells- in tumors [10,16,17,22]. However, the nature of periostin-producing cells in tumors is another matter of controversy as separate in situ hybridization experiments suggested that POSTN mRNA is detected in the cytoplasm of cancer cells [5,7].
###end p 11
###begin p 12
###xml 63 69 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 449 455 449 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3</italic>
###xml 95 100 <span type="species:ncbi:9606">human</span>
In this study, we relied on quantitative RT-PCR to investigate POSTN expression in a series of human normal tissues and tumors. We next focused on cutaneous melanoma to quantify periostin transcripts in a total of 113 tumor samples, including primary and metastatic lesions, and we correlated periostin expression with Breslow thickness of melanoma primary tumors. Finally, to investigate the source of periostin production in melanoma, we analyzed POSTN transcription level in 23 newly-established melanoma cell lines and matched tumors and compared the results with the expression level of COL6A3, a melanoma-associated stromal marker encoding the alpha3 chain of collagen VI.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
POSTN expression in normal tissues
###end title 14
###begin p 15
###xml 151 153 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 175 180 172 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 186 190 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 196 197 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 215 216 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 219 225 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 449 455 446 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 618 624 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 67 72 <span type="species:ncbi:9606">human</span>
We used qRT-PCR to quantify periostin expression in various normal human tissues. Values were normalized with the level of beta-actin expression (Fig. 1A) and given as [(cDNA POSTN/cDNA ACTB) x 104] (POSTN/ACTB x 104). POSTN was expressed in a wide range of normal tissues but the expression was negligible in PBLs and spleen. Expression was also very low in salivary gland and thymus. Tissue samples from skin and breast were characterized by high POSTN expression (average expression of 509 +/- 418 and 444 +/- 390 respectively) although levels were fluctuating significantly between independent samples. Similarly, POSTN expression levels measured in four independent ovarian tissues spanned over a broad range (from 0.5 +/- 0.02 to 151 +/- 17). Conversely, periostin expression levels in normal pancreas, liver, lymph node, lung or colon were more homogeneous.
###end p 15
###begin p 16
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantitative measurement of <italic>POSTN </italic>expression in human normal tissues and primary cultures</bold>
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 241 243 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 279 283 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 296 302 296 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 438 440 438 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 474 480 472 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 514 519 <span type="species:ncbi:9606">human</span>
Quantitative measurement of POSTN expression in human normal tissues and primary cultures. POSTN and ACTB cDNA levels were measured by qRT-PCR based on Taqman technology. For each sample, measurements were done in triplicate. POSTN/ACTB x 104 was calculated as [(cDNA POSTN/cDNA ACTB) x 104]. A. POSTN expression in normal tissues. Error bars represent standard deviations (SD). The table below the graph gives the average POSTN/ACTB x 104 +/- SD values for each sample. B. POSTN expression in primary cultures of human embryonic stem cells at day 5 (HUES), fetal lung fibroblasts (IMR90), newborn foreskin fibroblasts (HFF2) and adult skin fibroblasts (LB2924). Error bars represent SD.
###end p 16
###begin p 17
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 372 378 372 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 737 739 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 761 767 755 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
The above data suggest that tissues with low fibroblast content including PBLs, spleen, pancreas or liver show reduced POSTN expression compared to fibroblast-rich tissues like skin or breast. Together with previous observations that fibroblasts may be the source of periostin expression in various tumors [10,14,16,17], this suggests that fibroblast content may modulate POSTN expression level in normal tissues. To evaluate POSTN expression in fibroblasts, we extracted RNA from fibroblast primary cultures derived from either fetal lung (IMR90), newborn foreskin (HFF2) or adult abdominal skin (LB2924). POSTN expression levels as high as, respectively, 1547 +/- 213, 1391 +/- 142 and 1267 +/- 57 were measured in these samples (Fig. 1B). This high level of POSTN expression in fibroblasts was not a consequence of establishing primary cultures as embryonic stem cell primary cultures (HUES) were characterized by very low periostin expression level (4.2 +/- 0.5), further suggesting that periostin expression is not required at the blastocyst embryonic stage.
###end p 17
###begin title 18
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
POSTN expression in various tumors
###end title 18
###begin p 19
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
To evaluate the extent of periostin expression in tumors, we measured the amount of POSTN and ACTB cDNA molecules in hematological malignancies and tumors from pancreas, testis, liver, bladder, prostate, colon, stomach, ovary, lung, kidney and breast (Fig. 2).
###end p 19
###begin p 20
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of <italic>POSTN </italic>expression in normal tissues and tumors</bold>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 71 76 71 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
Comparison of POSTN expression in normal tissues and tumors. POSTN and ACTB cDNA levels were measured in triplicate in various normal tissues and tumors as described in Fig. 1 legend. Normal tissue samples correspond to samples from Fig. 1. POSTN/ACTB x 104 values are given as Mean +/- SD in normal tissues (grey bars) and tumors (black bars).
###end p 20
###begin p 21
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 244 250 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 417 420 411 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 453 455 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 489 495 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 540 542 530 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 593 595 581 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 601 603 589 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 631 637 619 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 807 810 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 822 824 806 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 895 901 879 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 941 944 923 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
###xml 971 973 951 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
In line with the absence of POSTN expression in normal PBLs, periostin expression levels were negligible in hematological malignancies including leukemia (0.2 +/- 0.2) and myeloma (1.5 +/- 3.6). Overall, our data reveal the huge variability of POSTN expression levels in most solid tumors and normal tissues. Hence, increased periostin expression was only nearly significant in pancreatic adenocarcinoma (656 +/- 819 vs 9.1 +/- 6.9 for normal pancreas, P = 0.06). In liver cancer, average POSTN expression was also increased (902 +/- 1308, n = 6) compared to normal tissue samples (14 +/- 11, n = 5) (P = 0.16). In ovarian tumors, POSTN expression levels were about 15-fold higher than the average level measured in a total of seven (three separate ovaries and one pool of four) normal tissues (759 +/- 708 vs 52 +/- 66) (P = 0.14). For lung cancer, we measured a significant 5-fold increase of POSTN expression in NSCLC tumors (272 +/- 177 vs 55 +/- 49 for normal lung, P = 0.002).
###end p 21
###begin title 22
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
POSTN expression in primary and metastatic melanoma lesions
###end title 22
###begin p 23
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 471 473 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 478 480 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 491 497 485 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 582 584 576 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Next, we investigated POSTN expression in 113 human cutaneous melanoma samples, including 46 primary lesions and 67 metastases. Periostin expression in melanoma was compared to the expression level in nine normal skin or benign nevus tissues (Fig. 3A). The average POSTN expression levels amounted to 500 +/- 369 in normal tissues, 489 +/- 961 in primary tumors and 1081 +/- 1878 in metastases. Although periostin expression levels were variable in melanoma tumors (Fig. 3A and 3B), average POSTN expression level was significantly higher in metastases compared to primary lesions (P = 0.03).
###end p 23
###begin p 24
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantitative analysis of <italic>POSTN </italic>expression in melanoma</bold>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 129 131 129 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 150 152 150 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 186 188 186 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 209 211 209 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 406 408 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 448 450 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 917 919 917 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
Quantitative analysis of POSTN expression in melanoma. A. POSTN and ACTB cDNA levels were measured in triplicate in normal skin (n = 6), benign nevi (n = 3) and melanoma primary tumors (n = 46) or metastases (n = 67) as described in Fig. 1 legend. Error bars represent SD. B. Data from panel A for normal tissues (N), primary tumors (P) and metastases (M) were classified into six ranges of POSTN/ACTB x 104 values. C. Comparison of POSTN/ACTB x 104 values between metastases and matched primary tumors from 11 patients or between distinct metastases from the same individual (patients LB2174, LB2201 and LB2077, with indication of tumor resection dates as MM.YY). Error bars represent SD. D. Metastatic tumors (Meta) were classified according to their localization (lymph node, liver or (sub)-cutaneous) and POSTN expression levels were compared to levels in tissue samples from normal organs (N). E. POSTN/ACTB x 104 values were measured in hepatic metastatic lesions from intraocular melanoma (Meta) and normal liver.
###end p 24
###begin p 25
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 461 467 461 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 641 647 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1096 1102 1096 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1160 1162 1160 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1177 1179 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 1229 1235 1229 1235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1395 1397 1395 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 1434 1440 1434 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1614 1620 1614 1620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1674 1676 1674 1676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 1679 1685 1679 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1807 1809 1807 1809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3E</xref>
###xml 1812 1814 1812 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
Melanoma metastases were characterized by highly variable POSTN expression levels. Notably, very low expression levels (<10) were measured in 9% of melanoma metastases while 15% of them showed very high levels of POSTN expression (>2000) (Fig. 3B). To further compare periostin expression in primary tumors and metastases, we measured the level of POSTN transcripts in metastases and matched primary tumors from 11 patients (Fig. 3C). No correlation was found: POSTN expression was either reduced (by up to 280-fold), maintained or increased (by up to 11-fold) in metastases compared to primary melanoma. Further analysis also revealed that POSTN transcription levels may vary significantly between distinct metastases isolated from the same individual (patients LB2174, LB2201 and LB2077, Fig. 3C). These variations may be explained by distinct localization of melanoma metastases as normal skin produces significant amounts of periostin unlike other organs with very low endogenous levels of periostin, like lymph nodes or the liver. Strikingly, our analysis revealed a significant increase of POSTN expression in more than 60% of tumor-invaded lymph nodes (P = 0.003) (Fig. 3D). Conversely, tumor-invaded lymph nodes with low POSTN expression account for the low levels (<100) measured in a subset of melanoma metastases. Similar observations were made with hepatic melanoma metastases (Fig. 3D). Hence, these data demonstrate the POSTN overexpression in about 60% of melanoma metastases in the liver or lymph nodes. Periostin overexpression in (sub)cutaneous melanoma metastases is more difficult to assess as POSTN transcripts are already abundant in normal skin (Fig. 3D). POSTN overexpression in metastatic tumors was confirmed by an analysis of 19 hepatic metastases from intraocular melanoma (Fig. 3E) (P = 0.002).
###end p 25
###begin p 26
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 477 483 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
Earlier reports suggested that periostin expression level was correlated with tumor aggressiveness and/or poorer survival in NSCLC [14,16], SCLC [17], neuroblastoma [15], colon cancers [6], thyroid carcinomas [11], oral squamous cell carcinoma [12] and pancreatic cancer [10]. Here, we relied on a revised version of Breslow classification based on primary tumor thickness [23] to correlate periostin expression with prognosis of melanoma (Fig. 4). Quantitative measurement of POSTN expression was performed on a total of 35 primary melanoma lesions. POSTN expression levels >300 were measured in only 9% of tumors with Breslow thickness </= 4 mm but were detected in 58% of tumors with Breslow thickness >4 mm. These data suggest that, in melanoma, increased tumor thickness may be correlated with increased periostin expression although tumoral cell content of samples is difficult to estimate and may vary with tumor thickness.
###end p 26
###begin p 27
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Correlation between <italic>POSTN </italic>expression and Breslow thickness of melanoma</bold>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 189 191 189 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 211 213 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 233 235 233 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
Correlation between POSTN expression and Breslow thickness of melanoma. POSTN and ACTB cDNA levels were measured in triplicate in primary tumors of melanoma with Breslow thickness <1.0 mm (n = 9), 1.01<>2.0 mm (n = 8), 2.01<>4.0 mm (n = 6) and >4.0 mm (n = 12) as described in Fig. 1 legend.
###end p 27
###begin title 28
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
POSTN expression in melanoma cell lines
###end title 28
###begin p 29
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
To gain more insight into the nature of periostin-producing cells in metastatic lesions, we measured POSTN expression levels in newly established melanoma cell lines and matched tumors. One major difference between melanoma tumor and cell line cDNA samples is the presence of stromal cell cDNA in tumors whereas cell lines derive from malignant cells exclusively.
###end p 29
###begin p 30
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 214 220 214 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 250 256 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 693 695 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5D</xref>
###xml 890 892 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 897 899 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 911 917 903 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1452 1454 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 781 788 <span type="species:ncbi:9606">patient</span>
###xml 875 883 <span type="species:ncbi:9606">patients</span>
###xml 1211 1218 <span type="species:ncbi:9606">patient</span>
###xml 1419 1427 <span type="species:ncbi:9606">patients</span>
We measured the level of POSTN transcripts in 23 melanoma cell lines and matched tumors (Fig. 5A). These melanoma lines were established in our laboratory and were subjected to no more than 4 to 11 passages before POSTN expression analysis. Overall, POSTN transcript abundance was decreased in most cell lines compared to tumors and expression levels were extremely low (from 0.06 +/- 0.01 to 3.4 +/- 0.3) in 11 cell lines. However, six cell lines, LB2077-1, LB2077-4, LB2730-1, LB2174-3, CP50-1B and LB2800, were characterized by higher periostin expression (between 149 +/- 21 and 3941 +/- 362) and, as expected for a secreted protein, periostin was detected in the conditioned medium (Fig. 5D). Interestingly, independent cell lines derived from distinct metastases of the same patient were associated with very different levels of periostin expression (LB2077 and LB2174 patients, Fig. 5A and 5B). Notably, POSTN expression level was <1 in LB2077-2 cell line derived from a breast metastasis whereas periostin was expressed at very high level in LB2077-1 (3941 +/- 362) and LB2077-4 (680 +/- 73) cell lines derived from metastases located, respectively, in scalp sub-cutaneous tissues and heart of the same patient. Data also suggest that high level of periostin expression in metastatic tumoral cells is not time-dependent as variable expression levels were observed during the tumor resection history of melanoma patients LB2174 and LB2077 (Fig. 5B).
###end p 30
###begin p 31
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 0 64 0 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of <italic>POSTN </italic>expression in melanoma tumors and cell lines</bold>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 934 940 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 944 951 944 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 1305 1310 1305 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 826 834 <span type="species:ncbi:9606">patients</span>
Comparison of POSTN expression in melanoma tumors and cell lines. A. A total of 23 melanoma cell lines (black bars) and matched metastatic tumors (grey bars) were assessed for POSTN and ACTB expression in triplicate as described in Fig. 1 legend. All melanoma cell lines were established in our laboratory and subjected to no more than 4 to 11 passages before RNA extraction. Metastases were isolated from tumor-invaded lymph nodes (LB2201-2, LB2730-1, LB2165-1, LB2117-3, LB2667-1a, LB2800, LB1448-2, LB2870, EB81-2), skin (DDHK0062, KUL81-2), sub-cutaneous tissues (EB124, CP50-1b, LB2174-1, LB2174-3, LB2077-1, LB2821, LB2181-2, LB2763-1, LB2259-1, LB2307-2, VUB105) or heart (LB2077-4). Error bars represent SD. B. POSTN expression level was measured in independent melanoma cell lines derived from distinct metastasis of patients LB2174, LB2730 and LB2077. Date of cell line establishment (MM.YY) is indicated above the bars. C. POSTN and COL6A3 cDNA levels were measured by qRT-PCR in 12 melanoma cell lines and matched tumors. Values are given as (expression in cell line/expression in tumor) x 100%. D. Periostin protein was analyzed in conditioned medium from LB2077-1 and LB2730-1 periostin-producing melanoma cell lines and from LB2181-2 and LB2667-1a melanoma cell lines, which do not express POSTN, as negative controls.
###end p 31
###begin p 32
###xml 371 377 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3</italic>
###xml 468 475 464 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 624 626 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 676 678 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 697 704 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 793 800 786 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 880 882 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 920 927 913 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 1044 1051 1037 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 1088 1090 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5C</xref>
###xml 1133 1139 1126 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
To follow the disappearance of stromal fibroblasts upon establishment of melanoma cell lines from tumor samples, we searched for a genetic marker of fibroblasts in melanoma. cDNA microarray analysis of a series of paired melanoma tumor and tumor-derived cell line samples revealed that a set of stromal genes, including the gene encoding the alpha3 chain of collagen VI, COL6A3, were systematically and significantly down-regulated in all cell lines (data not shown). COL6A3 encodes a fibrillar protein of the extracellular matrix believed to be involved in cell anchoring and signaling through interactions with integrins [24] and induced by TGF-beta1 in dermal fibroblasts [25], suggesting that COL6A3 is a good genetic marker for melanoma-associated stromal fibroblasts. Hence, we compared COL6A3 expression levels in 12 melanoma cell lines and matched tumors by qRT-PCR (Fig. 5C). In agreement with microarray data, COL6A3 expression was drastically reduced in all cell lines tested compared to matched tumors with cell line/tumor ratio of COL6A3 cDNA ranging from 0.03 to 1.5% (Fig. 5C). By comparison, cell line/tumor ratio of POSTN expression was smaller than 1% in only six cases; the ratio was comprised between 5 and 8% in three cases and higher than 25% in LB2077-1, LB2077-4 and LB2730-1.
###end p 32
###begin p 33
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 684 690 684 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 737 744 737 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 605 610 <span type="species:ncbi:9606">human</span>
All together, these data suggest that, in about half of the melanoma samples tested, POSTN expression is restricted to stromal cells while, in the other half, cancer cells are another source of periostinproduction. The detection of POSTN expression in a fraction of melanoma cell lines suggests either that normal melanocytes express periostin and that the expression is maintained in some melanoma cells or that normal melanocytes do not express periostin but may acquire the ability to express the gene during the tumorigenic process. To address that issue, we quantified periostin expression in normal human melanocytes. Unlike the expression profile detected in skin fibroblasts, POSTN expression was not detected in melanocytes and COL6A3 expression was very low (Fig. 6). Therefore, our data suggest that, in metastatic melanoma tumors, periostin expression can be induced in melanoma cells.
###end p 33
###begin p 34
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 38 45 38 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 0 112 0 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Quantitative measurement of <italic>POSTN </italic>and <italic>COL6A3 </italic>expression in primary cultures of skin fibroblastes and melanocytes</bold>
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 121 128 121 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3</italic>
###xml 315 319 315 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
Quantitative measurement of POSTN and COL6A3 expression in primary cultures of skin fibroblastes and melanocytes. POSTN, COL6A3 and ACTB cDNA levels were measured in triplicate in primary cultures of skin fibroblasts (LB2924) and melanocytes (NHEM and LB656). COL6A3/ACTB x 104 was calculated as [(cDNA COL6A3/cDNA ACTB) x 104]. Error bars represent SD.
###end p 34
###begin title 35
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
POSTN expression in other cancer cell lines
###end title 35
###begin p 36
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
Finally, to compare the periostin expression levels in other cancer cell lines with the values obtained in melanoma, we selected a series of 19 cell lines derived from tumors of various cancer types (Table 1). POSTN expression levels <5 were detected in 16/19 cancer cell lines whereas strong expression was detected in Hs578T breast cancer cell line and LB831 bladder carcinoma cell line. Intermediate expression level of 45 +/- 4 was measured in A172 glioblastoma cell line. Hence, these data suggest that expression of periostin by cancer cells is not restricted to melanoma cells but may also occur in other cancer types.
###end p 36
###begin p 37
Periostin expression in various cancer cell lines
###end p 37
###begin p 38
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1 </sup>
###xml 0 2 0 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><sup>1 </sup></bold>
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
1 (cDNA POSTN/cDNA ACTB) x 104
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 193 194 193 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 257 263 257 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 271 276 <span type="species:ncbi:9606">human</span>
The discrepancy between different studies regarding the expression level of POSTN in normal tissues and the recent observation that transcription of the gene is up-regulated in various tumors [8] prompted us to set up a quantitative RT-PCR assay to measure POSTN mRNA in human normal tissues and tumors.
###end p 40
###begin p 41
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 486 492 486 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1011 1017 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
In normal tissues, previous Northen blot experiments demonstrated that periostin is not expressed in PBLs, highly expressed in fetal tissues or serum but studies disagreed on the extent of POSTN expression in a series of other tissues [4,19,21]. Our data confirm the absence of POSTN transcription in both PBLs and spleen, in agreement with previous observations [4,19]. Salivary gland, thymus and embryonic stem cells were also characterized by very low expression levels. The highest POSTN cDNA levels were measured in colon, small intestine, breast and skin. However, in the three latter organs, as well as in kidney and ovaries, expression levels were highly fluctuating between tissue samples, providing a possible explanation for the discrepancies between previous studies. The diversity in cell type content among samples may possibly account for this variability. In that respect, skin samples contain different cell types including fibroblasts, keratinocytes and melanocytes for which we have measured POSTN expression levels of, respectively, about 1500, 50 (data not shown) and 0.
###end p 41
###begin p 42
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 344 350 344 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 794 795 794 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 826 832 826 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1086 1094 1086 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 1144 1150 1144 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1185 1187 1185 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1212 1218 1212 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1477 1483 1477 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1495 1497 1495 1497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1529 1535 1529 1535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1773 1774 1773 1774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1848 1855 1848 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 2027 2033 2027 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 2135 2141 2135 2141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 2285 2291 2285 2291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 2374 2375 2374 2375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 2464 2470 2464 2470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 944 952 <span type="species:ncbi:9606">patients</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
In tumors, leukemia and myeloma showed negligible levels of periostin expression whereas POSTN transcripts were detected in all solid tumors. We detected a 72-fold increase of POSTN transcription in pancreatic adenocarcinoma compared to normal tissues (P = 0.06), in line with previous studies reporting a 42- to more than 100-fold increase of POSTN mRNA level in pancreatic tumors [7,10]. In liver and ovarian tumors, average expression levels were increased by 65- and 15-fold respectively. The only evidences for increased periostin expression in liver cancer reported so far come from immunohistochemical analysis of tumor tissues [7]. In ovarian tumors, tumor-derived epithelial cells and ascites, previous semi-quantitative studies reported elevated levels of periostin mRNA and protein [4,9]. Previous studies reported POSTN up-regulation in about half of the NSCLC tumors [14] and a slight increase in periostin serum levels from NSCLC patients [16]. Higher periostin serum levels were also correlated with increasing T- or N-stage in SCLC patients [17] but, on the other hand, in situ mRNA hybridization suggested a down-regulation of POSTN gene transcription in SCLC tumors [19]. Our data suggest that POSTN transcription is increased by 5-fold in NSCLC tumors. No significant difference was measured for SCLC and NET tumors although more samples should be analyzed. Analysis of six colorectal tumors and three normal colon samples revealed only a 2-fold increase in POSTN expression (P = 0.16). The modest increase in POSTN transcription that we measured in colorectal tumor samples does not match previous data from a semi-quantitative study reporting considerable periostin overexpression in 25/29 pairs of matched normal colon tissue and colon tumor samples [6]. The reason for this is unclear but may be related to the fact that Bao et al. mainly focused on colon cancers with hepatic metastases. In breast and kidney tumors, the difference in periostin expression was not significant due to the highly variable POSTN expression levels measured in both normal and tumoral samples. The absence of significant increase in POSTN expression in breast tumors contrasts with the conclusions from a previous study in which expression in tumors was compared to the low level of POSTN mRNA in primary mammary epithelial cultures as reference for normal breast tissue [5]. Overall, for most tumor types tested in this study, our data revealed highly variable POSTN expression levels in both tumors and normal tissues, suggesting that larger numbers of samples should be tested to address periostin expression in tumors more significantly.
###end p 42
###begin p 43
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 710 716 710 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 870 876 870 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1030 1036 1030 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1066 1072 1066 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1273 1279 1273 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
In normal skin, melanocytes do not express POSTN but fibroblasts express the gene at high level. Investigation of 46 primary cutaneous melanoma lesions did not reveal any significant difference in average POSTN expression compared to normal tissues although we found that, in primary melanoma, thicker tumors (> 4 mm) may be correlated with increased periostin expression (P = 0.07). However, melanoma cell content of tumor samples is difficult to estimate and may vary with tumor thickness, leading to possible distortion of the data. In metastatic melanoma lesions, POSTN expression ranged from very low to very high levels compared to normal skin. Classification of melanoma metastases showed that very low POSTN expression levels are found in metastases located in organs with low endogenous periostin expression, like the liver or lymph nodes. In these organs, low POSTN expression levels are expected if melanoma cells do not produce periostin. Conversely, periostin levels should be high if melanoma metastases overexpress POSTN either through acquisition of POSTN expression by melanoma cells or to increased periostin expression in tumor-associated stromal cells. In that respect, about 60% of melanoma metastatic tumors in the liver or lymph nodes showed a clear POSTN overexpression compared to normal organs.
###end p 43
###begin p 44
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 437 444 437 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 947 953 947 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1090 1096 1090 1096 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1164 1165 1164 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1166 1167 1166 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1168 1169 1168 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1424 1430 1424 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1474 1476 1474 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1477 1479 1477 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1480 1482 1480 1482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1804 1806 1804 1806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1869 1875 1869 1875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1978 1980 1978 1980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 2660 2662 2660 2662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 2902 2904 2902 2904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 889 896 <span type="species:ncbi:9606">patient</span>
###xml 1911 1920 <span type="species:ncbi:10090">nude mice</span>
The nature of periostin-producing cells in tumors is still under debate as separate studies reported a production of periostin by stromal cells [10,16,17,22] whereas other experiments suggested that POSTN mRNA is detected in cancer cells [5,7]. To investigate the nature of periostin-producing cells in melanoma, periostin expression was measured in newly established melanoma cell lines and matched tumors. In cell lines, expression of COL6A3 stromal cell marker was reduced to less than 1% of the value measured in matched tumors whereas periostin was expressed (at either low or high level) in about half of the melanoma cell lines. Given that normal melanocytes do not express periostin, this study suggests that melanoma cells sometimes acquire the ability to express the gene during tumorigenesis. Our data also indicate that cell lines isolated from distinct metastases of the same patient may be characterized by either negligible or high POSTN expression, suggesting that periostin expression is acquired by melanocytes during the metastatic process. Previous studies reported low POSTN expression in most tumor-derived cell lines, whatever their origin [4,7,9,13,18,19,21] but most cancer cell lines tested had been established a long time before and subjected to extensive culture, making it difficult to establish whether the decreased expression in cancer cell lines was reflecting a loss of stromal-associated POSTN expression as suggested by some authors [10,16,17,22] or artifacts due to prolonged cell culture. The induction of periostin expression in melanoma cells may be a consequence of mutagenic events occuring during the tumorigenic processes or may be the result of interactions with stromal components previously reported to influence development and progression of carcinomas [26]. In that respect, earlier experiments showed an induction of POSTN expression in tumors recovered from nude mice injected with periostin-negative transformed cell lines [21] (although one cannot rule out the possibility that stromal cells themselves may be the source of periostin expression in these tumors). On the other hand, our data indicate that stromal cells are an important source of periostin production in melanoma tumors. In some instances, periostin expression levels were higher than 3000 in the tumor but negligible in matching cell lines, suggesting that periostin expression may be very high in tumor-associated stromal cells. In line with this, a significant increase in periostin expression was measured in fibroblast-like stellate cells from pancreatic ductal adenocarcinoma tumors, a cancer characterized by excessive desmoplasia [10]. Stromal cells have a prominent role in cancer progression and cancer-associated fibroblasts are believed to play a crucial role by producing growth factors, chemokines and extracellular matrix components that promote tumor angiogenesis [27].
###end p 44
###begin p 45
###xml 123 131 123 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 561 563 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 564 566 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 567 569 563 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
The increased expression of periostin in melanoma metastatic lesions that we identified in this study is in agreement with in vivo studies revealing that periostin overexpression promotes metastatic growth of cancer cells [5,6,20,28]. Hence, this work suggests that, in melanoma, periostin overexpression may also be involved in the process of metastasis. In line with this, two previous studies identified an up-regulation of integrin alphaV (ITGAV), one of the subunits of periostin receptor, as a predictive marker for melanoma metastasis in primary tumors [27,29,30].
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 636 642 636 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 706 712 706 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 1195 1201 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1356 1362 1356 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1562 1568 1562 1568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 1312 1319 <span type="species:ncbi:9606">patient</span>
Periostin was reported to promote cell survival and angiogenesis in tumors. Although cancer-associated POSTN overexpression is well documented for some tumor types, it is still uncertain for other ones. To date, no quantitative comparison of periostin expression in a large panel of normal and tumor tissues was available. In this study, we detected considerable variability of POSTN transcript levels among samples from the same tissue type, especially for tissues with variable stroma content. Overall, our results support previously reported increase of periostin expression in tumors from pancreas, liver and NSCLC but suggest that POSTN overexpression is not a general feature of tumors. In melanoma, POSTN transcription was not increased in primary lesions compared to normal skin but was correlated with Breslow thickness. On the other hand, about 60% of melanoma metastases from lymph nodes or the liver overexpress POSTN. Analysis of newly-established melanoma cell lines and matched metastases revealed that, although stromal cells -presumably fibroblasts- are mostly responsible for periostin production in melanoma metastases, melanoma cells sometimes acquire the ability to express POSTN at high level. This acquisition is associated with the metastatic process as distinct metastases from the same patient were associated with very different POSTN expression levels. Hence, this work reconciles previously published studies reporting conflicting data about the nature of periostin-producing cells in tumors (stromal or cancer cells) and identifies POSTN as a marker of metastasis in melanoma.
###end p 47
###begin title 48
Methods
###end title 48
###begin title 49
Chemicals
###end title 49
###begin p 50
###xml 222 226 <span type="species:ncbi:9913">calf</span>
Minimum Essential Medium (MEM), Iscove's Modified Dulbecco's Medium (IMDM), Dulbecco's Modified Eagle Medium (DMEM), trypsin-EDTA and essential amino acids were purchased from GIBCO (Invitrogen, Merelbeke, Belgium); fetal calf serum was from HyClone (Perbio Science, Aalst, Belgium); TriPure reagent from Roche Applied Science Diagnostics (Mannheim, Germany) and all other reagents were from Sigma Aldrich (Bornem, Belgium).
###end p 50
###begin title 51
Primary cultures, normal tissues, tumors and cell lines
###end title 51
###begin p 52
###xml 1875 1876 1863 1864 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1972 1974 1954 1956 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 266 271 <span type="species:ncbi:9606">human</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
###xml 1209 1216 <span type="species:ncbi:9606">patient</span>
###xml 2109 2113 <span type="species:ncbi:9913">calf</span>
IMR90 fetal lung fibroblasts were kindly provided by M. Ricchetti (Institut Pasteur, Paris, France); HFF-2 newborn foreskin fibroblasts were purchased from ATCC (Rockville, MD); LB2924 fibroblasts were isolated from adult abdominal skin in our laboratory and normal human epidermal melanocytes NHEM derived from foreskin were purchased from PromoCell GmbH (Heidelberg, Germany). Normal tissue and tumor samples were obtained from patients undergoing surgery or tumor resection between 1991 and 2006. Experimental procedures involving the use of biological material were approved by our Institutional Review Board. All patients gave informed consent. In general, tumor biopsies were obtained as part of screening procedures for participation in clinical immunotherapy trials. The informed consent mentioned that part of the tumor samples could be used for research purposes. In a few cases, anterior to 2002, oral informed consent was obtained. Surgical specimens were immediately frozen in liquid nitrogen and stored at -80degreesC until RNA extraction. Cell lines derived from melanoma, rhabdomyosarcoma, NSCLC, SCLC, renal cell carcinoma, bladder carcinoma and larynx epidermoid carcinoma were derived from patient specimens in our laboratory. HeLa, PA-1, A172, A375, Hs578T, MCF-7 and Capan-1 cell lines were purchased from ATCC. Cell lines derived from osteosarcoma (U2OS), hepatocarcinoma (Huh-7), stomach tumor (MZGC3) and pancreatic carcinoma (Panc-1) were kindly provided by, respectively, F. Fuks (Universite Libre de Bruxelles, Brussels, Belgium), A.H. Patel (University of Oxford, Oxford, UK), P. Coulie (Universite Catholique de Louvain, Brussels, Belgium) and C. Hill (Cancer Research UK, London, UK). Fibroblasts were maintained as a monolayer in MEM media supplemented with 1% essential amino acids at 37degreesC in a humidified atmosphere saturated with 5% CO2. All cancer cell lines were grown at 37degreesC in a humidified atmosphere saturated with 8% CO2 in IMDM except for U2OS and HeLa (DMEM) and MZ2 and LB23-1 (DMEM/Hepes/glucose) cell lines. All media were supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 mug/ml streptomycin.
###end p 52
###begin title 53
RNA extraction and reverse transcription
###end title 53
###begin p 54
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 425 428 424 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">18 </sub>
###xml 148 153 <span type="species:ncbi:9606">human</span>
###xml 637 642 <span type="species:ncbi:9606">human</span>
Total cellular RNA was extracted with TriPure reagent or by the guanidine-iosthiocyanate/cesium-chloride procedure [31]. RNA samples from 18 normal human tissues were purchased from either Clontech (Mountain View, CA) or AMBION (Austin, TX). RNA from LB656 melanocytes was kindly provided by L. Old (Ludwig Institute for Cancer Research, New-York). cDNA synthesis from 2 mug of total RNA was accomplished by extension with dT18 in the presence of 200 U M-MLV reverse transcriptase (Invitrogen, Merelbeke, Belgium) for 1 h at 42degreesC in a final volume of 20 mul. Reaction volume was then adjusted to 100 mul with water. cDNA from HUES human embryonic stem cells at day 5, synthesized as described above, was a kind gift of A. Loriot and C. de Smet (Ludwig Institute for Cancer Research, Brussels).
###end p 54
###begin title 55
Real-time quantitative PCR
###end title 55
###begin p 56
###xml 33 37 30 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 40 42 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 45 51 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 55 62 52 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 352 353 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 450 456 447 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 582 583 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 693 699 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 703 710 691 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 732 737 714 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
###xml 738 740 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 774 779 756 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 790 796 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3</italic>
###xml 810 814 792 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 914 920 896 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
###xml 933 940 915 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 1023 1027 1005 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB</italic>
###xml 1023 1027 1005 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ACTB</italic></sub>
###xml 1054 1059 1036 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 1054 1059 1036 1041 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>POSTN</italic></sub>
###xml 1090 1093 1072 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL</italic>
###xml 1094 1095 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1090 1096 1072 1078 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>COL</italic>6<italic>A</italic>3</sub>
Expression levels of beta-actin (ACTB) [32], POSTN and COL6A3 were measured by qRT-PCR based on TaqMan technology using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Primers, probes and qPCR Core Kit reagent were purchased from Eurogentec (Seraing, Belgium). Sequences of primers and probes are described in Table 2. POSTN primers were chosen in exon 3 and 5 respectively, allowing the amplification of all nine POSTN splicing variants. Reactions were done in a final volume of 25 mul with 200 nM primers, 100 nM probe, 200 muM dNTPs, 5 mM MgCl2, 0.625 U Hot Gold Star polymerase and 2.5 mul cDNA in 1x buffer. Annealing temperature was of 60degreesC for POSTN and COL6A3 and of 62degreesC for ACTB [32]. Amplicon sizes were of 186 bp (POSTN), 142 bp (COL6A3) and 613 bp (ACTB). Standard curve equations were established by serial dilutions of PCR-amplified cDNA fragments of POSTN (602 bp) and COL6A3 (304 bp). cDNA copy numbers were calculated using the following equations: log(cDNAACTB) = (Ct-38.5)/3.7; log(cDNAPOSTN) = (Ct-36.9)/3.35 and log(cDNACOL6A3) = (Ct-37.2)/3.4.
###end p 56
###begin p 57
Primers and probes used in qRT-PCR
###end p 57
###begin title 58
Immunoblotting analysis
###end title 58
###begin p 59
###xml 602 608 <span type="species:ncbi:9986">rabbit</span>
###xml 693 704 <span type="species:ncbi:3704">horseradish</span>
###xml 732 738 <span type="species:ncbi:9986">rabbit</span>
To detect secreted periostin in the supernatants, LB2077-1, LB2730-1 melanoma cells were grown in IMDM medium until 90-100% confluency and thereafter kept in serum-free IMDM for 48 hours. LB2181-2 and LB2667-1a cell lines were used as negative controls. Four ml-supernatants from 400 000 cells were collected after 72 hours and concentrated 10 times using the Microsep centrifugal devices 10 K (Pall Life Sciences, Ann Arbor, MI). Equal volumes of concentrated supernatants were subjected to 7% SDS-PAGE and electroblotted onto a PVDF membrane (Millipore). The membrane was incubated successively with rabbit polyclonal antibody (ab14041, Abcam, Cambridge, UK) specific for periostin and then horseradish peroxidase-conjugated anti-rabbit IgG (Stressgen, Ann Arbor, MI). Protein bands were visualized using the Luminol Reagent (Santa Cruz Biotechnology).
###end p 59
###begin title 60
Statistical analysis
###end title 60
###begin p 61
###xml 8 9 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN </italic>
Student t-test was applied to compare POSTN expression in different sample series.
###end p 61
###begin title 62
List of abbreviations
###end title 62
###begin p 63
POSTN, periostin; 
###end p 63
###begin p 64
ACTB, beta-actin; 
###end p 64
###begin p 65
COL6A3, alpha3 chain of collagen VI; 
###end p 65
###begin p 66
qRT-PCR, quantitative reverse transcription-polymerizing chain reaction; 
###end p 66
###begin p 67
SCLC, small cell lung cancer; 
###end p 67
###begin p 68
NSCLC, non-small cell lung cancer; 
###end p 68
###begin p 69
NET, neuroendocrine tumor; 
###end p 69
###begin p 70
TGF-beta1, transforming growth factor-beta1; 
###end p 70
###begin p 71
SD, standard deviation; 
###end p 71
###begin p 72
PBL, peripheral blood lymphocyte.
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The author(s) declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">POSTN</italic>
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL6A3 </italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACTB </italic>
GT and MM carried out the quantitative RT-PCR analysis for POSTN, COL6A3 and ACTB genes. MM performed the immunoblot analysis. FB collected tumor samples, established cancer cell lines, synthesised cDNA from a series of samples and helped to draft the manuscript. NVB participated in the melanoma fibroblast marker selection and helped to draft the manuscript. AD conceived the study, participated in its design and coordination, performed the statistical analysis and drafted the manuscript. All authors read and approved the final manuscript.
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
We are grateful to Madeleine Swinarska for her excellent technical skills. We thank L. Old, O. Kholmanskikh, A. Loriot and C. de Smet for sharing reagents and M. Ricchetti, F. Fuks, P. Coulie, A.H. Patel and C. Hill for the gift of fibroblasts and cell lines. We are grateful to B. Lethe for his help with quantitative PCR analysis and for sharing reagents for ACTB PCR. This work was supported by the Fonds National de la Recherche Scientifique (FNRS). G.T. and M.M. are supported by PhD fellowship grants from Televie/FNRS and FRIA/FNRS.
###end p 78
###begin article-title 79
Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I
###end article-title 79
###begin article-title 80
###xml 76 86 <span type="species:ncbi:7227">Drosophila</span>
Sequence analysis and neuronal expression of fasciclin I in grasshopper and Drosophila
###end article-title 80
###begin article-title 81
Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro
###end article-title 81
###begin article-title 82
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility
###end article-title 82
###begin article-title 83
###xml 36 41 <span type="species:ncbi:9606">human</span>
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression
###end article-title 83
###begin article-title 84
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway
###end article-title 84
###begin article-title 85
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway
###end article-title 85
###begin article-title 86
Periostin: novel diagnostic and therapeutic target for cancer
###end article-title 86
###begin article-title 87
Differential gene expression between normal and tumor-derived ovarian epithelial cells
###end article-title 87
###begin article-title 88
Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity
###end article-title 88
###begin article-title 89
Gene expression in poorly differentiated papillary thyroid carcinomas
###end article-title 89
###begin article-title 90
Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer
###end article-title 90
###begin article-title 91
Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma
###end article-title 91
###begin article-title 92
Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers
###end article-title 92
###begin article-title 93
Expression of the periostin mRNA level in neuroblastoma
###end article-title 93
###begin article-title 94
Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas
###end article-title 94
###begin article-title 95
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer
###end article-title 95
###begin article-title 96
###xml 42 47 <span type="species:ncbi:9606">human</span>
Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells
###end article-title 96
###begin article-title 97
###xml 47 52 <span type="species:ncbi:9606">human</span>
Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene
###end article-title 97
###begin article-title 98
Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation
###end article-title 98
###begin article-title 99
Periostin induction in tumor cell line explants and inhibition of in vitro cell growth by anti-periostin antibodies
###end article-title 99
###begin article-title 100
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients
###end article-title 100
###begin article-title 101
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
###end article-title 101
###begin article-title 102
Integrin and Arg-Gly-Asp dependence of cell adhesion to the native and unfolded triple helix of collagen type VI
###end article-title 102
###begin article-title 103
Identification of novel TGF-beta /Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach
###end article-title 103
###begin article-title 104
Stromal fibroblasts in cancer initiation and progression
###end article-title 104
###begin article-title 105
Fibroblasts in cancer
###end article-title 105
###begin article-title 106
Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer
###end article-title 106
###begin article-title 107
Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis
###end article-title 107
###begin article-title 108
A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis
###end article-title 108
###begin article-title 109
Expression of BORIS in melanoma: lack of association with MAGE-A1 activation.
###end article-title 109

